Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Evrard D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, Abitbol C, Paradis V, Raymond E, Albert S, Barry B, Faivre S.

Oral Oncol. 2019 Jan;88:29-38. doi: 10.1016/j.oraloncology.2018.10.040. Epub 2018 Nov 20. Review.

PMID:
30616794
2.

Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

Purcell Y, Copin P, Paradis V, Vilgrain V, Ronot M.

Br J Radiol. 2019 Jan 10:20180701. doi: 10.1259/bjr.20180701. [Epub ahead of print]

PMID:
30604641
3.

Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.

Laouirem S, Sannier A, Norkowski E, Cauchy F, Doblas S, Rautou PE, Albuquerque M, Garteiser P, Sognigbé L, Raffenne J, van Beers BE, Soubrane O, Bedossa P, Cros J, Paradis V.

Oncogene. 2018 Dec 21. doi: 10.1038/s41388-018-0597-1. [Epub ahead of print]

PMID:
30575815
4.

Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.

Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, Erkan M, Kleeff J, Wilson J, Apte M, Tosolini M, Wilson AS, Delvecchio FR, Bousquet C, Paradis V, Hammel P, Sadanandam A, Kocher HM.

J Pathol. 2018 Dec 21. doi: 10.1002/path.5224. [Epub ahead of print]

PMID:
30575030
5.

[A liver tumor in an immunodeficient patient].

Depoilly T, Poté N, Cazals-Hatem D, Paradis V.

Ann Pathol. 2018 Dec 12. pii: S0242-6498(18)30137-8. doi: 10.1016/j.annpat.2018.07.012. [Epub ahead of print] French. No abstract available.

PMID:
30553638
6.

Proteomic Landscape of Cholangiocarcinomas Reveals Three Different Subgroups According to Their Localization and the Aspect of Non-Tumor Liver.

Le Faouder J, Gigante E, Léger T, Albuquerque M, Beaufrère A, Soubrane O, Dokmak S, Camadro JM, Cros J, Paradis V.

Proteomics Clin Appl. 2018 Dec 6:e1800128. doi: 10.1002/prca.201800128. [Epub ahead of print]

PMID:
30520266
7.

Obesity-induced pancreatopathy in rats is reversible after bariatric surgery.

Rebours V, Garteiser P, Ribeiro-Parenti L, Cavin JB, Doblas S, Pagé G, Bado A, Couvineau A, Ruszniewski P, Paradis V, Le Gall M, Van Beers BE, Couvelard A.

Sci Rep. 2018 Nov 2;8(1):16295. doi: 10.1038/s41598-018-34515-3.

8.

Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary Syndrome.

Lejealle C, Paradis V, Bruno O, de Raucourt E, Francoz C, Soubrane O, Lebrec D, Bedossa P, Valla D, Mal H, Vilgrain V, Durand F, Rautou PE.

Chest. 2019 Jan;155(1):123-136. doi: 10.1016/j.chest.2018.09.017. Epub 2018 Oct 4.

PMID:
30292761
9.

Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition.

Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell LD, Gill RM, Hytiroglou P, Nakanuma Y, Paradis V, Quaglia A, Rautou PE, Theise ND, Thung S, Tsui WMS, Sempoux C, Snover D, van Leeuwen DJ; International Liver Pathology Study Group.

Histopathology. 2019 Jan;74(2):219-226. doi: 10.1111/his.13738. Epub 2018 Oct 17. Review.

PMID:
30129657
10.

Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver.

Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, Rautou PE, Albuquerque M, Picq O, Gupta AC, Ferrere G, Gilgenkrantz H, Kiaf B, Toubal A, Beaudoin L, Lettéron P, Moreau R, Lehuen A, Lotersztajn S.

Nat Commun. 2018 Jun 1;9(1):2146. doi: 10.1038/s41467-018-04450-y.

11.

Acute-on-chronic liver failure 2018: a need for (urgent) liver biopsy?

van Leeuwen DJ, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell L, Gill RM, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Rautou PE, Sempoux C, Snover DC, Theise ND, Thung SN, Tsui WMS, Quaglia A, Liver Pathology Study Group TI.

Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):565-573. doi: 10.1080/17474124.2018.1481388. Epub 2018 Jun 14. Review.

PMID:
29806950
12.

Hepatocellular nodules in vascular liver diseases.

Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P.

Virchows Arch. 2018 Jul;473(1):33-44. doi: 10.1007/s00428-018-2373-6. Epub 2018 May 26. Review.

PMID:
29804132
13.

Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.

Bienaimé F, Ambolet A, Aussilhou B, Brazier F, Fouchard M, Viau A, Barre P, Tissier AM, Correas JM, Paradis V, Terzi F, Friedlander G, Knebelmann B, Joly D, Prié D.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2319-2328. doi: 10.1210/jc.2018-00123.

PMID:
29618028
14.

Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.

Payancé A, Silva-Junior G, Bissonnette J, Tanguy M, Pasquet B, Levi C, Roux O, Nekachtali O, Baiges A, Hernández-Gea V, Laouénan C, Lebrec D, Albuquerque M, Paradis V, Moreau R, Valla D, Durand F, Boulanger CM, Garcia-Pagan JC, Rautou PE.

Hepatology. 2018 Oct;68(4):1508-1518. doi: 10.1002/hep.29903. Epub 2018 May 21.

PMID:
29603327
15.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
16.

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.

Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc'h K, Manceau H, Gouya L.

J Intern Med. 2018 Jul;284(1):78-91. doi: 10.1111/joim.12750. Epub 2018 Mar 26.

PMID:
29498764
17.

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T.

Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.

18.

Benign and malignant hepatocellular lesions in patients with vascular liver diseases.

Vilgrain V, Paradis V, Van Wettere M, Valla D, Ronot M, Rautou PE.

Abdom Radiol (NY). 2018 Aug;43(8):1968-1977. doi: 10.1007/s00261-018-1502-7.

PMID:
29460040
19.

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N.

Hepatology. 2018 Jul;68(1):113-126. doi: 10.1002/hep.29789. Epub 2018 May 9.

PMID:
29360137
20.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
21.

Noninvasive assessment of liver steatosis in deceased donors: A pilot study.

Cesaretti M, Poté N, Cauchy F, Dondero F, Dokmak S, Sepulveda A, Schneck AS, Francoz C, Durand F, Paradis V, Soubrane O.

Liver Transpl. 2018 Apr;24(4):551-556. doi: 10.1002/lt.25002. No abstract available.

PMID:
29272077
22.

Volumetric measurement of hepatic tumors: Accuracy of manual contouring using CT with volumetric pathology as the reference method.

Pupulim LF, Ronot M, Paradis V, Chemouny S, Vilgrain V.

Diagn Interv Imaging. 2018 Feb;99(2):83-89. doi: 10.1016/j.diii.2017.11.002. Epub 2017 Dec 6.

PMID:
29221936
23.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

PMID:
29150490
24.

Cystic fibrosis liver disease in adults: Limits of noninvasive tests of fibrosis.

Hillaire S, Cazals-Hatem D, Erlinger S, Paradis V.

Hepatology. 2017 Nov 3. doi: 10.1002/hep.29637. [Epub ahead of print] No abstract available.

PMID:
29105109
25.

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.

Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J.

Nat Commun. 2017 Nov 3;8(1):1315. doi: 10.1038/s41467-017-01358-x.

26.

Testing feasibility of an accurate microscopic assessment of macrovesicular steatosis in liver allograft biopsies by smartphone add-on lenses.

Cesaretti M, Poté N, Dondero F, Cauchy F, Schneck AS, Soubrane O, Paradis V, Diaspro A, Antonini A.

Microsc Res Tech. 2018 Jan;81(1):58-63. doi: 10.1002/jemt.22956. Epub 2017 Oct 17.

PMID:
29044859
27.

Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences.

Barbier L, Ronot M, Aussilhou B, Cauchy F, Francoz C, Vilgrain V, Soubrane O, Paradis V, Belghiti J.

Hepatology. 2018 Aug;68(2):652-662. doi: 10.1002/hep.29582. Epub 2018 Jul 11.

PMID:
29023812
28.

Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study.

Poté N, Cauchy F, Albuquerque M, Cros J, Soubrane O, Bedossa P, Paradis V.

Liver Int. 2018 Apr;38(4):687-694. doi: 10.1111/liv.13585. Epub 2017 Sep 24.

PMID:
28872754
29.

Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy.

Hillaire S, Cazals-Hatem D, Bruno O, de Miranda S, Grenet D, Poté N, Soubrane O, Erlinger S, Lacaille F, Mellot F, Vilgrain V, Paradis V.

Liver Transpl. 2017 Oct;23(10):1342-1347. doi: 10.1002/lt.24842. No abstract available.

30.

Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition.

Cazals-Hatem D, Billiauws L, Rautou PE, Bondjemah V, Poté N, Corcos O, Paradis V, Joly F.

Liver Int. 2018 Jan;38(1):174-182. doi: 10.1111/liv.13545. Epub 2017 Sep 2.

PMID:
28792647
31.

Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness.

Sharma S, Maras JS, Das S, Hussain S, Mishra AK, Shasthry SM, Sharma CB, Weiss E, Elkrief L, Rautou PE, Gilgenkrantz H, Lotersztajn S, Paradis V, de la Grange P, Junot C, Moreau R, Sarin SK.

Sci Rep. 2017 Jul 28;7(1):6816. doi: 10.1038/s41598-017-07161-4.

32.

Molecular classification of hepatocellular adenoma in clinical practice.

Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J.

J Hepatol. 2017 Nov;67(5):1074-1083. doi: 10.1016/j.jhep.2017.07.009. Epub 2017 Jul 19. Review.

PMID:
28733222
33.

Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy.

de Lédinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V.

Dig Dis Sci. 2017 Sep;62(9):2569-2577. doi: 10.1007/s10620-017-4638-3. Epub 2017 Jun 2.

PMID:
28577247
34.

Tri-directional anaphases as a novel chromosome segregation defect in human oocytes.

Haverfield J, Dean NL, Nöel D, Rémillard-Labrosse G, Paradis V, Kadoch IJ, FitzHarris G.

Hum Reprod. 2017 Jun 1;32(6):1293-1303. doi: 10.1093/humrep/dex083.

35.

Variant differentiation patterns in primary liver carcinoma.

Sempoux C, Paradis V, Saxena R.

Semin Diagn Pathol. 2017 Mar;34(2):176-182. doi: 10.1053/j.semdp.2017.02.001. Epub 2017 Feb 8.

PMID:
28256363
36.

Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content.

Akl M, Hindawi AE, Mosaad M, Montasser A, Ray AE, Khalil H, Anas A, Atta R, Paradis V, Hadi AA, Hammam O.

Open Access Maced J Med Sci. 2016 Dec 15;4(4):578-584. doi: 10.3889/oamjms.2016.122. Epub 2016 Nov 15.

37.

IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans.

Alzaid F, Lagadec F, Albuquerque M, Ballaire R, Orliaguet L, Hainault I, Blugeon C, Lemoine S, Lehuen A, Saliba DG, Udalova IA, Paradis V, Foufelle F, Venteclef N.

JCI Insight. 2016 Dec 8;1(20):e88689.

38.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

PMID:
27939373
39.

Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.

Wu Z, Galmiche A, Liu J, Stadler N, Wendum D, Segal-Bendirdjian E, Paradis V, Forgez P.

Cancer Lett. 2017 Mar 1;388:73-84. doi: 10.1016/j.canlet.2016.11.032. Epub 2016 Dec 1.

PMID:
27914862
40.

Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.

Bedossa P, Tordjman J, Aron-Wisnewsky J, Poitou C, Oppert JM, Torcivia A, Bouillot JL, Paradis V, Ratziu V, Clément K.

Gut. 2017 Sep;66(9):1688-1696. doi: 10.1136/gutjnl-2016-312238. Epub 2016 Nov 24. Review.

PMID:
27884920
41.

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.

de Vries EM, de Krijger M, Färkkilä M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hübscher SG, Verheij J, Ponsioen CY.

Hepatology. 2017 Mar;65(3):907-919. doi: 10.1002/hep.28963. Epub 2017 Jan 11.

PMID:
27880989
42.

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.

Cauchy F, Mebarki M, Leporq B, Laouirem S, Albuquerque M, Lambert S, Bourgoin P, Soubrane O, Van Beers BE, Faivre S, Bedossa P, Paradis V.

Clin Sci (Lond). 2017 Jan 1;131(1):27-36. Epub 2016 Nov 1.

PMID:
27803295
43.

Hepatic Fibrosis, Inflammation, and Steatosis: Influence on the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease.

Leitão HS, Doblas S, Garteiser P, d'Assignies G, Paradis V, Mouri F, Geraldes CF, Ronot M, Van Beers BE.

Radiology. 2017 Apr;283(1):98-107. doi: 10.1148/radiol.2016151570. Epub 2016 Oct 27.

PMID:
27788034
44.

Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.

Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.

Liver Transpl. 2016 Nov;22(11):1491-1500. doi: 10.1002/lt.24615.

45.

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L.

J Hepatol. 2017 Feb;66(2):424-441. doi: 10.1016/j.jhep.2016.09.010. Epub 2016 Sep 26. Review.

PMID:
27686679
46.

Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden.

Ronot M, Cauchy F, Gregoli B, Breguet R, Allaham W, Paradis V, Soubrane O, Vilgrain V.

HPB (Oxford). 2016 Aug;18(8):684-90. doi: 10.1016/j.hpb.2016.05.012. Epub 2016 Jun 18.

47.

Development of Collateral Pathways in Tumor Obstruction of Confluence of the Hepatic Veins: Neither Fortuitous nor Innocuous.

Barbier L, Ronot M, Monsinjon M, Paradis V, Soubrane O, Vilgrain V, Belghiti J.

J Am Coll Surg. 2016 Oct;223(4):595-601. doi: 10.1016/j.jamcollsurg.2016.06.013. Epub 2016 Jun 29.

PMID:
27374994
48.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

PMID:
27353036
49.

Diabetes mellitus in patients with cirrhosis: clinical implications and management.

Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R.

Liver Int. 2016 Jul;36(7):936-48. doi: 10.1111/liv.13115. Epub 2016 Apr 4. Review.

PMID:
26972930
50.

Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.

Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ; International Liver Pathology Study Group.

Histopathology. 2016 Jun;68(7):953-67. doi: 10.1111/his.12957. Epub 2016 Apr 28. Review.

PMID:
26918878

Supplemental Content

Loading ...
Support Center